#Denmark #Board of Directors #Lundbeck #Annual General Meeting #Valby

Lundbeck's Annual General Meeting: Key Decisions and Future Directions

On March 26, 2025, H. Lundbeck A/S convened its Annual General Meeting at its headquarters, marking a significant moment for the biopharmaceutical company dedicated to brain health. This meeting not only ratified vital reports and decisions but also set the stage for Lundbeck's strategies moving forward in a rapidly evolving healthcare landscape.

During the gathering, shareholders adopted the report presented by the Board of Directors and subsequently approved the annual report, reflecting a commitment to transparency and accountability. A highlight of the meeting was the decision to distribute a dividend amounting to 30% of the net profit for the fiscal year 2024, translating to DKK 0.95 per share, which totals approximately DKK 946 million.

The meeting also saw the re-election of several board members, including Dorothea Wenzel, who continues her role as Chair, alongside Lene Skole-Sørensen as Deputy Chair. New member Lars Green joined the board, enhancing Lundbeck's governance structure. The new board composition aims to leverage a robust blend of experience, bringing diverse perspectives crucial for navigating the complexities of the biopharmaceutical sector.

As part of the governance changes, several committees were established to enhance Lundbeck's operational effectiveness:

• - The Audit Committee includes Lars Green (Chair), Jeffrey Berkowitz, and Lars Erik Holmqvist, focusing on financial integrity and oversight.
• - The Remuneration and Nomination Committee is chaired by Dorothea Wenzel alongside Lene Skole-Sørensen and Jeffrey Berkowitz to drive comprehensive compensation strategies and talent acquisition.
• - The Scientific Committee, chaired by Santiago Arroyo with members including Lene Skole-Sørensen, Dorothea Wenzel, and Jakob Riis, will delve into Lundbeck's research initiatives, ensuring alignment with the latest advancements in neuroscience.

A pivotal aspect of the meeting involved approving the remuneration for the Board of Directors for the year 2025, reflecting the company's long-term vision and commitment to aligning board members' interests with those of shareholders. Furthermore, PricewaterhouseCoopers was re-elected to audit the company's financials along with the sustainability reporting, underscoring Lundbeck's dedication to responsible business practices.

The board was granted authorization to acquire treasury shares, which is geared towards enhancing shareholder value and maintaining financial flexibility in market conditions. This strategic move allows Lundbeck to manage its capital structure effectively while potentially bolstering its stock performance.

Additionally, amendments to the Articles of Association were approved to facilitate the forthcoming merger between the Capitol Region of Denmark and Region Zealand. This demonstrates Lundbeck's proactive approach to navigating regulatory changes and ensuring compliance with evolving legal frameworks.

The updated Remuneration Policy introduced shareholding requirements for the Board and the potential increase in the pay-out structure under the Long-Term Incentive Program for executive management aims to align compensation with performance and long-term strategic goals. This initiative illustrates Lundbeck's intent to cultivate a culture of ownership and accountability among its leaders.

Post-meeting, the Chair of the general meeting was empowered to file the resolutions with the Danish Business Authority, ensuring these decisions are officially recognized. With no other business on the agenda, the assembly marked a decisive step forward for Lundbeck as it continues its mission to enhance brain health through innovative therapies.

The commitment to improving brain health not only guides Lundbeck's operations but also influences its approach to corporate responsibility and societal well-being. With a workforce of around 5,500 and a presence in over 50 countries, Lundbeck is steadfast in its pursuit of transformative medical solutions within the neurological and psychiatric domains, addressing unmet needs with dedication and rigor.

Lundbeck aims to maintain a trajectory of growth and innovation as it tackles global challenges in mental health, ensuring lasting value not just for its shareholders, but for patients and society alike. For deeper insights into Lundbeck's strategic direction and initiatives, we invite you to explore their corporate website and connect via LinkedIn.